Oxford Biomedica reported today of the first three patients in the Phase I/II gene therapy trial at Henri Mondor Hospital, Paris:

'The three ProSavin-treated patients at the first dose level have reached their three-month assessments. There were no adverse events associated with the surgical procedure for administration of ProSavin into the brain. All three patients were ambulatory within 24 hours of the procedure (i.e. capable of walking and not bedridden). Similarly, there have been no serious or unexpected post treatment-related safety issues to date.'

Specific data will be released in a few weeks.

A good start at least

Report today from trial:

'There were no serious adverse events associated with the surgical procedure for administration of ProSavin into the brain. All three patients were ambulatory within 48 hours of the procedure. At three months post ProSavin
administration, patients showed an improvement of 23-30% as measured by the UPDRS 'off' score. This measures the degree of mobility in the absence of standard of care dopaminergic therapies. Two patients showed improvements in Quality of Life measures (QoL) that are specific to patients with Parkinson's disease, and one patient's QoL was unchanged.'

They're going to start upping the dose this month.